Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia

Ajda Drofenik; Ales Blinc; Mojca Bozic Mijovski; Tadej Pajic; Matjaz Vrtovec; Matjaz Sever

doi:10.2478/raon-2024-0036

.blurhash-client-img { display: none !important; }

Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia

Radiology and Oncology

Volume 58 (2024): Issue 4 (December 2024)

By: Ajda Drofenik, Ales Blinc, Mojca Bozic Mijovski, Tadej Pajic, Matjaz Vrtovec and Matjaz Sever

Open Access

|Oct 2024

Abstract

Background

JAK2 V617F (JAK2) mutation is associated with clonal hemopoiesis in myeloproliferative neoplasms as well as with faster progression of cardiovascular diseases. Little is known about the relationship between allele burden and the degree of atherosclerotic alteration of coronary vasculature. We previously reported that carotid artery stiffness progressed faster in patients with JAK2 positive essential thromocythemia (ET) patients. After a four-year follow-up we investigated whether mutation burden of a JAK2 allele correlates with a higher coronary calcium score.

Patients and methods

Thirty-six patients with JAK2 positive ET and 38 healthy matched control subjects were examined twice within four years. At each visit clinical baseline characteristics and laboratory testing were performed, JAK2 mutation burden was determined, and coronary calcium was measured.

Results

JAK2 allele burden decreased in 19 patients, did not change in 5 patients, and increased in 4 patients. The coronary calcium Agatston score increased slightly in both groups. Overall, there was no correlation between JAK2 allele burden and calcium burden of coronary arteries. However, in patients with the JAK2 mutation burden increase, the coronary calcium score increased as well.

Conclusions

The average JAK2 allele burden decreased in our patients with high-risk ET during the four-year period. However, in the small subgroup whose JAK2 mutation burden increased the Agatston coronary calcium score increased as well. This finding, which should be interpreted with caution and validated in a larger group, is in line with emerging evidence that JAK2 mutation accelerates atherosclerosis and can be regarded as a non-classical risk factor for cardiovascular disease.

References

Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 2015; 1: 97–105. doi: 10.1001/jamaoncol.2015.89
Open DOI Search in Google Scholar Back to article
Chuzi S, Stein BL. Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leuk Lymphoma 2017; 58: 2786–2798. doi: 10.1080/10428194.2017.1312371
Open DOI Search in Google Scholar Back to article
Bousoik E, Montazeri Aliabadi H. “Do we know Jack” about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol 2018; 8: 287. doi: 10.3389/fonc.2018.00287
Open DOI Search in Google Scholar Back to article
Babakhanlou R, Masarova L, Verstovsek S. A review of essential thrombocythemia and its complications. Clin Adv Hematol Oncol 2023; 21: 76–84. PMID: 36780473
Search in Google Scholar Back to article
Misaka T, Kimishima Y, Yokokawa T, Ikeda K, Takeishi Y. Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F. J Cardiol 2023; 81: 3–9. doi: 10.1016/j.jjcc.2022.02.001
Open DOI Search in Google Scholar Back to article
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017; 377: 111–21. doi: 10.1056/NEJMoa1701719
Open DOI Search in Google Scholar Back to article
Anžič Drofenik A, Vrtovec M, Božič Mijovski M, Sever M, Preložnik Zupan I, Kejžar N, et al. Progression of coronary calcium burden and carotid stiffness in patients with essential thrombocythemia associated with JAK2 V617F mutation. Atherosclerosis 2020; 296: 25–31. doi: 10.1016/j.atherosclerosis.2020.01.001
Open DOI Search in Google Scholar Back to article
Vrtovec M, Anzic A, Preložnik Zupan I, Zaletel K, Blinc A. Carotid artery stiffness, digital endothelial function, and coronary calcium in patients with essential thrombocytosis, free of overt atherosclerotic disease. Radiol Oncol 2017; 51: 203–10. doi: 10.1515/raon-2017-0006
Open DOI Search in Google Scholar Back to article
Ipsogen JAK2 MutaQuant Kit Handbook. Version 1(Catalog no. 673523). Hilden, Germany: QIAGEN GmbH. 2013. p. 1–48.
Search in Google Scholar Back to article
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–32. doi: 10.1016/0735-1097(90)90282-t
Open DOI Search in Google Scholar Back to article
Leiva O, Gabriela Hobbs G, Ravid K, Libby P. Cardiovascular disease in myeloproliferative neoplasms. JACC CardioOncology state-of-the-art review. JACC CardioOncol 2022; 4: 166–82. doi: 10.1016/j.jaccao.2022.04.002
Open DOI Search in Google Scholar Back to article
Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun 2017; 85: 58–63. doi: 10.1016/j.jaut.2017.06.010
Open DOI Search in Google Scholar Back to article
Genovese E, Mirabile M, Rontauroli S, Sartini S, Fantini S, Tavernari L, et al. The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis. Antioxidants 2022; 11: 113. doi: 10.3390/antiox11010113
Open DOI Search in Google Scholar Back to article
Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol Dis 2012; 49: 170–6. doi: 10.1016/j.bcmd.2012.06.004
Open DOI Search in Google Scholar Back to article
Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice. Circ Res 2018; 123: e35–47. doi: 10.1161/CIRCRESAHA.118.313283
Open DOI Search in Google Scholar Back to article
Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J Clin Invest 2018; 128: 4359–71. doi: 10.1172/JCI90312
Open DOI Search in Google Scholar Back to article
Yang X, Jia J, Yu Z, Duanmu Z, He H, Chen S, et al. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit. BMC Cardiovasc Disord 2020; 20: 133. doi: 10.1186/s12872-020-01391-7
Open DOI Search in Google Scholar Back to article
Solli CN, Chamat-Hedemand S, Elming H, Ngo A, Kjaer L, Skov V, et al. High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol 2023; 111: 400–6. doi: 10.1111/ejh.14019
Open DOI Search in Google Scholar Back to article
Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93: 41–8. doi: 10.3324/haematol.11653
Open DOI Search in Google Scholar Back to article
Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–84. doi: 10.1002/cncr.22663
Open DOI Search in Google Scholar Back to article
Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–9. doi: 10.1038/sj.leu.2403902
Open DOI Search in Google Scholar Back to article
Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96: 315–8. doi: 10.3324/haematol.2010.031070
Open DOI Search in Google Scholar Back to article
Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098–100. doi: 10.1182/blood-2005-08-3395
Open DOI Search in Google Scholar Back to article
Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21: 1952–9. doi: 10.1038/sj.leu.2404854
Open DOI Search in Google Scholar Back to article
Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–13. doi: 10.1111/j.1365-2141.2005.05764.x
Open DOI Search in Google Scholar Back to article
Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, et al. Impact of JAK2V617F mutation burden on disease phenotype in chinese patients with JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET). Int J Med Sci 2016; 13: 85–91. doi: 10.7150/ijms.10539
Open DOI Search in Google Scholar Back to article
Lee AJ, Kim SG, Nam JY, Yun J, Ryoo HM, Bae SH. Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res 2021; 56: 259–65. doi: 10.5045/br.2021.2021089
Open DOI Search in Google Scholar Back to article
Yow KS, Liu X, Chai CN, Tung ML, Yan B, Christopher D, et al. Relationship of JAK2 (V617F) allelic burden with clinicohaematological manifestations of Philadelphia-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev 2020; 21: 2805–10. doi: 10.31557/APJCP.2020.21.9.2805
Open DOI Search in Google Scholar Back to article
Popova-Labachevska M, Panovska-Stavridis I, Eftimov A, Kapedanovska NA, Cevreska L, Ivanovski M, et al. Evaluation of the JAK2V617F mutational burden in patients with Philadelphia chromosome negative myeloproliferative neoplasms: a single-center experience. Balkan J Med Genet 2019; 22: 31–6. doi: 10.2478/bjmg-2019-0021
Open DOI Search in Google Scholar Back to article
Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 2012; 32: 385–91. doi: 10.3343/alm.2012.32.6.385
Open DOI Search in Google Scholar Back to article
Trifa AP, Bănescu C, Voina CM, Popa Ș, Török-Vistai T, Bojan AS, et al. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia. Blood Cells Mol Dis 2018; 73: 45–6. doi: 10.1016/j.bcmd.2018.09.003
Open DOI Search in Google Scholar Back to article
Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, et al. Comparison of JAK2 V617 -positive essential thrombocythaemia and early primary myelofibrosis: the impact of mutation burden and histology. Hematol Oncol 2018; 36: 269–75. doi: 10.1002/hon.2430
Open DOI Search in Google Scholar Back to article
Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 2018; 8: 2. doi: 10.1038/s41408-017-0041-8
Open DOI Search in Google Scholar Back to article
Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 2009; 183: 2089–96. doi: 10.4049/jimmunol.0900477
Open DOI Search in Google Scholar Back to article
Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121: 1720–8. doi: 10.1182/blood-2012-07-443770
Open DOI Search in Google Scholar Back to article
Birgegård G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica 2018; 103: 51–60. doi: 10.3324/haematol.2017.174672
Open DOI Search in Google Scholar Back to article
Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, et al. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Des Devel Ther 2015; 9: 2687–94. doi: 10.2147/DDDT.S79576
Open DOI Search in Google Scholar Back to article
Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica 2010; 95: 1435–8. doi: 10.3324/haematol.2009.021444
Open DOI Search in Google Scholar Back to article
Zalcberg IR, Ayres-Silva J, de Azevedo AM, Solza C, Daumas A, Bonamino M. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden. Haematologica 2011; 96: e18–20. doi: 10.3324/haematol.2010.037846
Open DOI Search in Google Scholar Back to article
Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418–24. doi: 10.1200/JCO.2009.23.6075
Open DOI Search in Google Scholar Back to article
Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013; 122: 893–901. doi: 10.1182/blood-2012-07-442012
Open DOI Search in Google Scholar Back to article
Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 2015; 126: 2585–91. doi: 10.1182/blood-2015-07-659060
Open DOI Search in Google Scholar Back to article
Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 2015; 126: 1551–4. doi: 10.1182/blood-2015-03-635235
Open DOI Search in Google Scholar Back to article
Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood 2017; 130: 1768–71. doi: 10.1182/blood-2017-02-765032
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/raon-2024-0036 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 565 - 572

Submitted on: Mar 24, 2024

Accepted on: Jun 1, 2024

Published on: Oct 4, 2024

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

essential thrombocythemia,

JAK2 V617F mutation,

JAK2 V617F allele burden,

coronary calcium score

Related subjects:

Medicine,

Clinical medicine,

Internal medicine,

Haematology, oncology,

Radiology

© 2024 Ajda Drofenik, Ales Blinc, Mojca Bozic Mijovski, Tadej Pajic, Matjaz Vrtovec, Matjaz Sever, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 58 (2024): Issue 4 (December 2024)